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Cost-eﬀ ectiveness of Xpert MTB/RIF and investing in health 
care in Africa
The Xpert MTB/RIF assay is an accurate test for the 
diagnosis of tuberculosis when an adequate sputum 
sample can be obtained; even in smear-negative 
tuberculosis the sensitivity is about 67%.1,2 Although 
the assay turnaround time is under 2 h, depending on 
the health-care setting, time to tuberculosis treatment 
can be 2 weeks or more in a substantial number of 
patients.3 The technology has now been endorsed by 
WHO as a frontline test for tuberculosis in populations 
where there is a high incidence of HIV.4 Indeed, 
several countries in Africa are rolling out Xpert MTB/
RIF.5 However, for expanded and sustained uptake, 
governments and policy makers require information 
about the cost-eﬀ ectiveness of the technology to allow 
for appropriate planning and allocation of health-care 
resources. Cost-eﬀ ectiveness must be balanced against 
aﬀ ordability and sustainability. Thus, although the 
diagnostic accuracy of the technique is not in doubt, 
questions remain about the cost-eﬀ ectiveness of the 
technology given that the overall number of patients 
treated for tuberculosis can remain unchanged6 and 
given the high rates of empirical treatment in resource-
poor health-care settings.7
Modelling studies have estimated that the imple-
mentation of Xpert MTB/RIF, either in addition to or as a 
replacement to smear microscopy, will be cost-eﬀ ective 
for the diagnosis of tuberculosis and mutidrug-resistant 
(MDR) tuberculosis in countries with a high burden.8–11 
The incremental cost of each disability-associated 
life-year averted by Xpert implementation (the 
incremental cost-eﬀ ectiveness ratio [ICER]) is below 
the WHO-deﬁ ned “willingness to pay” threshold for all 
settings modelled by Vassal and colleagues,10 and the 
ﬁ ndings of Menzies and colleagues suggest that Xpert 
implementation could, through improved case-ﬁ nding 
and treatment, sub stantially reduce tuberculosis illness 
and death.11
However, these studies diﬀ ered in their assumptions 
about disease transmission, rates of MDR tuberculosis, 
duration and eﬀ ect of future disease burden, 
downstream eﬀ ects of antiretroviral therapy, and 
how the relevant health-care system models were 
constructed. Thus, further data are required about the 
cost-eﬀ ectiveness of diﬀ erent algorithmic strategies on 
health-care systems in Africa. In this issue of The Lancet 
Global Health, Ivor Langley and colleagues12 assess the 
cost-eﬀ ectiveness of diﬀ erent diagnostic strategies on 
cost-eﬀ ectiveness within the context of the Tanzanian 
health-care system. These strategies included a com-
bination of conventional smear microscopy (Ziehl 
Nielson staining), LED microscopy (conventional 
versus same day), full roll-out of Xpert MTB/RIF, and 
LED microscopy followed by targeted Xpert in smear-
negative cases (the latter two strategies in either all HIV-
infected persons or only those known be HIV-infected). 
They found, using an integrated modelling approach, 
that full roll-out of Xpert MTB/RIF was the most cost-
eﬀ ective option with the potential to substantially 
reduce national tuberculosis burden, and that targeted 
use of Xpert MTB/RIF after microscopy in HIV-infected 
people was a less cost-eﬀ ective approach. The latter was 
less cost-eﬀ ective because of the reduced likelihood of 
preventing death and reduction in the potential gain 
in life-years owing to the shortened lifespan in HIV-
infected people.
However, there are several limitations to these 
ﬁ ndings. Current diagnostic practice, especially the 
frequency, timing, and accuracy of clinical diagnoses 
or empirical tuberculosis treatment, is highly setting-
speciﬁ c, dependent on adherence to the WHO algorithm 
for smear-negative tuberculosis,13 and can reduce the 
cost-eﬀ ectiveness of diagnostic interventions.7,14 Langley 
and colleagues’ estimated sensitivity of smear-negative 
tuberculosis in Tanzania (52%)15 is lower than that from 
a recent meta-analysis,16 and the authors also assumed 
excellent speciﬁ city (95%). In South Africa, for example, 
most smear-negative patients seem to be “detected” 
through empirical treatment, and, as seen in Uganda 
and Kenya,17,18 less than half of notiﬁ ed cases are micro-
biologically conﬁ rmed, suggesting that signiﬁ cant 
overtreatment is occurring.6
Furthermore, patient-level costs were not included and 
these are known to be substantial and inﬂ uence default, 
particular in tuberculosis-endemic countries.19 The 
targeted use of Xpert MTB/RIF after smear microscopy 
was only explored in HIV-infected participants and not 
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HIV-uninfected people. The ICER also diﬀ ered substantially 
from other studies.10 However, this must be understood 
within the context of diﬀ erent assumptions about 
transmission, future disease burden, and antiretroviral 
therapy, among other factors. MDR tuberculosis was not 
considered in the transmission component and therefore 
one wonders about applicability to other settings with 
high rates of MDR tuberculosis, such as South Africa. 
However, the higher rates of MDR tuberculosis would 
probably have made the Xpert MTB/RIF strategy even 
more cost-eﬀ ective in this context. 
One could further debate many nuances of the 
internal workings of the models and their external 
validity in replicating or predicting outcomes in the 
priority areas for tuberculosis intervention, but perhaps 
it is not reasonable to ask too much of a single study. 
We would argue that sensitivities of the model to 
particular assumptions warrant further discussion, and 
be interpreted not just as limitations but as ﬂ ags that 
inform programmatic implementation.
Despite these limitations, several of which are 
acknowledged by Langley and colleagues,12 the study 
adds important information to the current knowledge 
base, and not only conﬁ rms but quantiﬁ es the cost-
eﬀ ectiveness of Xpert MTB/RIF in the Tanzanian 
setting. It further provides crucial information about 
the magnitude of investment that must be made by 
African governments for full roll-out of Xpert MTB/RIF. 
Tuberculosis is now the commonest cause of death in 
many African countries and has a signiﬁ cant eﬀ ect on 
national gross domestic products (GDPs). It therefore 
makes economic sense to invest in health-care systems 
and to roll out technologies such as nucleic acid 
ampliﬁ cation tests. However, knowledge translation 
is now required to aﬀ ect the decision making process 
at program matic level, and thereafter monitor post-
implementation operational and epidemiological 
indicators. However, the potential gains of Xpert MTB/
RIF can only be realised if several other operational and 
logistic aspects of the health-care system, as a whole, 
are addressed including communication and transport 
infrastructure, capacity of the national treatment 
programme, and investing in eﬃ  cient reporting 
systems, among others, so that the impact of Xpert 
MTB/RIF can be realised on the ground.
Most importantly, however, it is time for governments 
and policy makers to invest in health care so that the 
potential gains of newer technologies such as Xpert 
MTB/RIF can be translated into reduced morbidity and 
mortality, and positively aﬀ ect the GDPs of African 
economies. There are several indications that Africa 
is entering a golden age of economic prosperity and 
it is hoped that investment in health-care systems 
and infrastructure will parallel this boom. The data by 
Langley and colleagues inform this agenda.
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